Charles River Laboratories | CRL - Ebitda

Aktienkurs
166.79
Täglich Wechseln
-4.44 -2.59%
Monatlich
4.43%
Jährlich
42.20%
Q2 Prognose
166.17




Ebitda Veränderung Datum
Agilent USD 540M 74M 2025-09
Align Technology USD 183.84M 19.77M 2025-09
Bio-Rad Laboratories USD -374.6M 841.8M 2025-09
Bruker USD 211.6M 207.4M 2025-12
Cardinal Health USD 981M 5M 2025-12
Charles River Laboratories USD 258.06M 24.83M 2025-12
Cigna USD 2.86B 56M 2025-03
CVS Health USD 3.74B 349M 2025-12
Danaher USD 1.92B 204M 2026-03
Dentsply International USD 135M 32M 2025-12
Elevance Health USD 4.21B 2.02B 2026-03
Galapagos EUR 2.42M 161.13M 2025-09
Humana USD -290M 1.11B 2025-12
Illumina USD 332M 12M 2025-09
Incyte USD 414.5M 92.42M 2025-12
Intrexon USD -24.7M 2.92M 2024-06
IQVIA Holdings USD 1.05B 97M 2025-12
Laboratory Of America USD 588.1M 24.1M 2025-12
Lonza CHF 1.01B 54M 2025-12
McKesson USD 1.68B 418M 2025-09
Merck EUR 1.44B 263M 2025-12
Mettler Toledo International USD 322.64M 26.75M 2025-09
Novartis USD 4.77B 1.11B 2025-12
Pfizer USD 6.08B 351M 2025-09
Quest Diagnostics USD 557M 20M 2026-03
Revvity USD 248.91M 48.52M 2025-12
Thermo Fisher Scientific USD 2.7B 464M 2026-03
United Therapeutics USD 379.5M 83.4M 2025-12
UnitedHealth USD 9.99B 8.5B 2026-03
Veradigm USD 38.81M 29.61M 2022-09
Waters USD 380.97M 85.83M 2025-12
West Pharmaceutical Services USD 226.2M 7.7M 2026-03